hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia

Leukemia. 2010 Jun;24(6):1243-5. doi: 10.1038/leu.2010.86. Epub 2010 May 6.

Authors

A Bazeos, D Marin, A G Reid, G Gerrard, D Milojkovic, P C May, H de Lavallade, P Garland, K Rezvani, J F Apperley, J M Goldman, L Foroni, J S Khorashad

PMID: 20445576
DOI: 10.1038/leu.2010.86

No abstract available

Publication types

Letter

MeSH terms

Antineoplastic Agents / therapeutic use*
Benzamides
Fusion Proteins, bcr-abl / genetics
Fusion Proteins, bcr-abl / metabolism
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Octamer Transcription Factor-1 / genetics*
Octamer Transcription Factor-1 / metabolism
Piperazines / therapeutic use*
Polymorphism, Single Nucleotide / genetics*
Prognosis
Pyrimidines / therapeutic use*
RNA, Messenger / genetics
RNA, Messenger / metabolism
Reverse Transcriptase Polymerase Chain Reaction

Substances

Antineoplastic Agents
Benzamides
Octamer Transcription Factor-1
POU2F1 protein, human
Piperazines
Pyrimidines
RNA, Messenger
Imatinib Mesylate
Fusion Proteins, bcr-abl